Southeast Asset Advisors LLC Sells 7,935 Shares of Revvity, Inc. (NYSE:RVTY)

Southeast Asset Advisors LLC cut its holdings in Revvity, Inc. (NYSE:RVTY) by 41.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,413 shares of the company’s stock after selling 7,935 shares during the quarter. Southeast Asset Advisors LLC’s holdings in Revvity were worth $1,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC lifted its holdings in Revvity by 2.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,214 shares of the company’s stock worth $470,000 after buying an additional 100 shares during the period. HB Wealth Management LLC lifted its stake in Revvity by 4.6% in the fourth quarter. HB Wealth Management LLC now owns 2,380 shares of the company’s stock worth $266,000 after acquiring an additional 104 shares during the period. Signaturefd LLC lifted its stake in Revvity by 6.8% in the fourth quarter. Signaturefd LLC now owns 1,668 shares of the company’s stock worth $186,000 after acquiring an additional 106 shares during the period. Westside Investment Management Inc. boosted its holdings in Revvity by 0.8% in the fourth quarter. Westside Investment Management Inc. now owns 14,363 shares of the company’s stock valued at $1,603,000 after acquiring an additional 108 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its position in Revvity by 5.1% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,247 shares of the company’s stock valued at $286,000 after purchasing an additional 110 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Stock Performance

Shares of RVTY stock opened at $94.79 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The company has a market capitalization of $11.39 billion, a price-to-earnings ratio of 42.89, a price-to-earnings-growth ratio of 3.82 and a beta of 1.07. Revvity, Inc. has a one year low of $93.54 and a one year high of $129.50. The company’s 50-day moving average is $113.18 and its 200 day moving average is $116.43.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same quarter in the previous year, the business earned $1.25 EPS. Sell-side analysts expect that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. The ex-dividend date is Thursday, April 17th. Revvity’s dividend payout ratio is currently 12.67%.

Insider Activity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares of the company’s stock, valued at approximately $4,232,782. The trade was a 31.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now owns 19,652 shares of the company’s stock, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on RVTY shares. Barclays raised their target price on shares of Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Raymond James reaffirmed an “outperform” rating and set a $145.00 price objective (up from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Bank of America raised Revvity from a “neutral” rating to a “buy” rating and set a $138.00 target price for the company in a research report on Friday, December 13th. KeyCorp lifted their price target on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Sanford C. Bernstein cut Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price target on the stock. in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.